No reduced serum serotonin levels in patients with post-acute sequelae of COVID-19
We postulate that peripheral serotonin is no reliable biomarker for PASC and that it should not be used in routine diagnostic. Therapy of PASC with serotonin-reuptake inhibitors or tryptophane supplementation should not be based solely on the assumption of lowered serotonin levels.
Authors
- Stefanie Pfau (ORCID: https://orcid.org/0000-0003-2658-3980)
- Veronika Götz (ORCID: https://orcid.org/0000-0003-3223-8745)
- Philipp Mathé (ORCID: https://orcid.org/0000-0002-0448-5338)
- Maike Hofmann (ORCID: https://orcid.org/0000-0001-8410-8833)
- Siegbert Rieg (ORCID: https://orcid.org/0000-0001-7493-7080)
- Katarina Stete
- Hanna Hilger
- Dietrich Walzer
- Winfried V. Kern
Institutions
- University Medical Center Freiburg (DE)
Publication Details
- Journal
- Infection
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1007/s15010-024-02397-5
- Citations
- 4
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 1.48